Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Quality of life over time after new onset refractory status epilepticus
Gruen, Matthew D. , Jimenez, Anthony D. , Batra, Ayush , Blank, Leah J. , Damien, Charlotte , Day, Gregory S. , Eschbach, Krista , Gofton, Teneille , Hantus, Stephen , Kang, Peter , Kim, Minjee , Madani, Bahar, Morales, M., Punia, Vineet , Taraschenko, Olga , Torcida, Nathan , Wainwright, Mark S. , Yoo, Ji Yeoun , Wong, Nora , Batra, Ayush , Blank, Leah J , Damien, Charlotte , Eschbach, Krista , Gofton, Teneille E , Jette, Nathalie , Punia, Vineet , Taraschenko, Olga , Yoo, Ji Yeoun , Hirsch, Lawrence J , Hanin, Aurelie , Wainwright, Mark S , Day, Gregory S , Kim, Minjee , Gopaul, Margaret , Gerard, Elizabeth E. , Jetté, Nathalie , Jongeling, Amy , Kazazian, Karnig , Kellogg, Marissa , Steriade, Claude , Struck, Aaron F. , Gaspard, Nicolas , Wong, Nora, Hirsch, Lawrence J. , Hanin, Aurélie

Epilepsia | September 13, 2025 | Volume: 67 | Issue: 1 | Pages: 328-340

10.1111/epi.18635 | PMID 40944696 Get It

Abstract Objective This study aims to better characterize the long‐term neurological quality of life (QOL) outcomes (using the Neuro‐QOL scale) in survivors of new onset refractory status epilepticus (NORSE), including its subtype febrile infection‐related epilepsy syndrome (FIRES), and provide guidance for psychological and social support strategies. Methods Utilizing data from a multicenter prospective study of NORSE/FIRES led by Yale University, we enrolled patients who completed the validated, patient‐reported Neuro‐QOL scale at least once at 3–6 months ( n = 37), 12 months ( n = 29), 24 months ( n = 23), or ≥36 months ( n = 9) following discharge. The Neuro‐QOL scale assesses physical, mental, and social health in patients with neurological disorders. QOL impairment (QOL‐I) scores were calculated, with higher scores indicating greater impairment. T ‐scores enabled comparisons with reference populations. Results In adults, median QOL‐I improved from 44.1% at 3–6 months to 37.6% at 36+ months. Paired analysis showed significant improvement in QOL‐I between 3–6 and 24 months ( p = .016), with specific improvements in communication, satisfaction with social roles, fatigue, and mobility. Greater improvement was also observed for participation in social roles (5.5‐point T ‐score gain) compared to the reference population, suggesting meaningful change. A gradual improvement in overall QOL‐I scores was also observed in pediatric participants, despite a modest sample size ( n = 5 with data at 3–6 and 12 months). Measures of fatigue and anxiety persisted in adults, and cognitive difficulties persisted in both adults and children. In adults, longer status epilepticus duration and intensive care unit stay were associated with poorer QOL. Additionally, a higher number of antiseizure medications was associated with more depression, cognitive impairments, and perceived stigma. Significance These findings highlight the potential for recovery following an acute episode of NORSE, although many patients continue to face challenges requiring ongoing support, and the clinical meaning of the reported QOL improvement remains unclear. Furthermore, the findings underscore the importance of strategic multidisciplinary support systems in the years following discharge.
Third‐Generation Bruton tyrosine kinase  Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance ( MGTS)
Man, Louise , Kanack, Adam J. , Mauch, Emily, Splinter, Noah P., Padmanabhan, Anand , Mauch, Emily E, Padmanabhan, Anand

American Journal of Hematology | September 13, 2025 | Volume: 100 | Issue: 12 | Pages: 2377-2381

10.1002/ajh.70078 | PMID 40944630 Get It

Extracellular matrix stiffness conditions glioblastoma cells for long-term migration: Mechanical memory as a driver of invasion and recurrence in glioblastoma
Meade, Paola Suarez, Whitehead, Rachel, Rosenfeld, Steve, Quiñones‐Hinojosa, Alfredo , Schiapparelli, Paula , Quinones-Hinojosa, Alfredo , Whitehead, Rachel, Κωνσταντόπουλος, Κωνσταντίνος

Neuro-Oncology | September 13, 2025 | Volume: 28 | Issue: 1 | Pages: 19-37

10.1093/neuonc/noaf205 | PMID 40973065 Get It

Abstract Extracellular matrix (ECM) stiffening correlates with tumor invasion in various cancer types, including glioblastoma (GBM). Increased matrix stiffness promotes a migratory phenotype through dysregulation of cell-ECM bidirectional communication. Exposure to stiffer environments is sensed by cells, which then adapt in ways that promote invasive behavior. These adaptive changes are imprinted onto the cells and persist even after they are placed in new, softer microenvironments via a process known as “mechanical memory.” Mechanical memory is believed to be driven by mechanosensitive transcription factor activity and epigenetic remodeling. Glioblastoma recurrence is linked to the ability of cells to disperse and infiltrate the surrounding healthy tissue. Extracellular matrix stiffness in GBM is heterogeneous; it starts with a softer tumor core and becomes progressively stiffer toward the tumor’s edges, potentially promoting sustained tumor invasion through mechanical memory. This review discusses the role of ECM stiffness in cancer cell behavior and the implications of ECM stiffening in GBM. We then describe the findings associated with mechanical memory and relay underlying mechanisms currently understood to drive the preservation of mechanically primed phenotypes. Finally, we discuss how matrix stiffness can drive migratory phenotypes in GBM cells and the potential role that progressive ECM dysregulation at the tumor periphery can link the formation of invasive tumor niches to the aggressive, resistant, and mesenchymal-like phenotypes present in GBM recurrent tumors.
Real-world performance of diagnostic testing for coccidioidal meningitis in initial sampling of the cerebrospinal fluid
Ravi, Niriksha , Elkurdi, Rawan, Lietz, Alexander J , Grys, Thomas E. , Grill, Marie , Blair, Janis E. , Kurdi, Rana , El Kurdi, Rawan , Grys, Thomas E , Lietz, Alexander J

Medical Mycology | September 13, 2025 | Volume: 63 | Issue: 9 | Pages: No page available

10.1093/mmy/myaf082 | PMID 40971610 Get It

Abstract Early diagnosis and treatment are essential for improving outcomes of coccidioidal meningitis. While the detection of IgG by serologic testing of the cerebrospinal fluid (CSF) has been a mainstay of diagnosis for years, the diagnosis of coccidioidal meningitis in clinical practice can be very challenging due to suboptimal sensitivity of laboratory tests. We reviewed the results of the CSF diagnostic test results from the initial lumbar puncture in 110 patients with proven, probable, and likely coccidioidal meningitis from 1989 to 2024. One hundred four patients were diagnosed with coccidioidal meningitis on the initial CSF examination. The positivity rate of the first CSF testing was 89.1% (n = 64) for IgG by enzyme immunoassay, 62.2% (n = 98) for IgG by immunodiffusion, and 70.2% (n = 104) for IgG by complement fixation, 4.4% (n = 90) for fungal culture, 18.8% (n = 69) for polymerase chain reaction, and 33% (n = 21) for Coccidioides antigen. The non-specific fungal marker 1,3-β-d-glucan was positive in the CSF in 70.4% (n = 27) of samples. Contrasted brain magnetic resonance imaging identified leptomeningeal enhancement in 53.1%. Optimal detection of coccidioidal meningitis requires a combination of diagnostic modalities.
Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals
Sato‐Espinoza, Karina , Vierkant, Robert A. , Chotiprasidhi, Perapa , Tian, Shulan , Ma, Jun , O’Brien, Daniel R. , Lazaridis, Konstantinos N. , Dlugosch, Carola, Schneider, Carolin V. , Wangensteen, Kirk J. , Vairo, Filippo , Tian, Shulan , Ma, Jun , O'Brien, Daniel , Lazaridis, Konstantinos N , Dlugosch, Carola , Scheider, Carolin , Allen, Alina M , Wangensteen, Kirk J , Sato-Espinoza, Karina , Vierkant, Robert A , Vairo, Filippo Pinto e , Allen, Alina M.

Liver International | September 13, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1111/liv.70300 | PMID 40944478 Get It

ABSTRACT Background & Aims Steatotic liver disease (SLD) is characterised by liver fat accumulation exceeding 5%. Lean body weight (BMI ≤ 25 kg/m 2 ) with non‐alcoholic SLD is a rare phenotype, and the balance of risks related to metabolic conditions or genetic predisposition, or the risk of progressive liver disease, is not known. This study evaluates clinical and genetic predictors of non‐alcoholic SLD and advanced liver disease in lean individuals. Methods We used International Classification of Disease codes, radiology and pathology review to identify 177 lean non‐alcoholic SLD cases (47 cryptogenic, 130 MASLD), 677 matched lean controls, and 3090 overweight/obese SLD cases in the Mayo Clinic Biobank and Tapestry databases. We performed case–control and cross‐sectional comparisons of clinical and genetic factors between these groups, using univariable and multivariable analyses. Results Lean individuals with non‐alcoholic SLD exhibited metabolic and genetic profiles that were intermediate between those of lean controls without SLD and overweight/obese SLD individuals, including intermediate rates of diabetes, hypertension, hyperlipidaemia and of homozygosity for the risk allele of PNPLA3 . Multivariable analysis indicated that diabetes was an independent predictor of SLD among lean individuals. Among lean individuals with non‐alcoholic SLD, those with metabolic‐associated SLD (MASLD), as compared to those with cryptogenic SLD (without metabolic risk factor), were more likely to be homozygous for risk alleles in GCKR . The Fib‐4 score, a tool for screening advanced liver disease in SLD, accurately predicted advanced fibrosis among lean individuals with non‐alcoholic SLD. Conclusion Diabetes serves as a primary predictor of non‐alcoholic SLD in lean individuals. These results support the recommendation to screen for SLD in patients with diabetes, regardless of BMI. The GCKR risk allele is associated with MASLD in lean individuals, and the risk factors for cryptogenic SLD remain unclear.
Diagnostic yield of cardiac computed tomography in detecting high-risk cardioaortic embolic sources: A retrospective cohort study
Osman, Khansa , Liu, Michael , Mohammed, Marwa A. , Young, Phillip M. , Nasr, Deena M. , Nasr, Deena , Ghozy, Sherief

International Journal of Stroke | September 13, 2025 | Volume: 21 | Issue: 4 | Pages: 552-558

10.1177/17474930251381131 | PMID 40944425 Get It

Background: Ischemic stroke remains a leading cause of morbidity and mortality worldwide. Cardioembolic sources account for a significant proportion of these events, necessitating accurate identification of underlying structural heart abnormalities. Traditionally, transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) have been utilized for this purpose, although both have limitations. Cardiac computed tomography (CCTA) has emerged as a potential alternative, offering non-invasive imaging with high sensitivity and specificity for detecting intracardiac thrombi. Objective: This study aimed to evaluate the diagnostic yield of CCTA compared to TTE and TEE in detecting high-risk cardioaortic sources of embolism, including left ventricular (LV) thrombus, left atrial (LA) thrombus, valvular thrombus, and ulcerated aortic plaques, in patients with ischemic stroke. Methods: We conducted a retrospective, single-center cohort study at Mayo Clinic, Rochester, MN, including 426 ischemic stroke patients who underwent CCTA within 30 days of stroke onset between March 2019 and June 2023. We compared the diagnostic yields of CCTA, TTE, and TEE in detecting structural cardiac sources of embolism. Results: The overall diagnostic yield of CCTA for detecting high-risk cardioaortic sources was 15.5%. Specifically, CCTA identified LV thrombus in 2.3% of patients, LA thrombus in 4.0%, valvular thrombus in 2.8%, and ulcerated aortic plaques in 7.0%. In comparative analysis, CCTA demonstrated a higher yield than TTE (16.0% vs 3.5%, p < 0.001) and a comparable yield to TEE (25.3% vs 20.7%, p = 0.47) in detecting these sources. Conclusions: CCTA proved to be a viable option for identifying high-risk structural sources of cardioembolism in ischemic stroke patients. Its non-invasive nature, coupled with the ability to perform imaging soon after stroke onset, underscores its clinical utility. However, further prospective and blinded studies are required to validate these findings and fully establish the efficacy of CCTA in this context.
Adverse Reactions to Phenol Neurolysis: Report of Severe Necrosis and Infection Following Genicular Nerve Ablation
Morodomi, Michael D, Cortes, Melissa P. , Smerina, Michael , Gavrancic, Tatjana , Pagán, Ricardo J. , Khanijo, Aditya , Gopikrishnan, Nilaa, Baptista, Aleksandra Murawska , Dumitrascu, Adrian G, Khanijo, Aditya A, Dumitrascu, Adrian

Clinical Case Reports | September 13, 2025 | Volume: 13 | Issue: 9 | Pages: No page available

10.1002/ccr3.70885 | PMID 40948702 Get It

ABSTRACTThis report details a severe complication of phenol neurolysis in a diabetic patient, where phenol induced tissue necrosis can lead to severe cellulitis with ulceration that may prove difficult to treat. It emphasizes the importance of considering comorbidities when selecting phenol neurolysis for treatment of chronic pain.
Improving Proteomic Dynamic Range with Multiple Accumulation Precursor Mass Spectrometry
Phlairaharn, Teeradon , Shannon, Ariana E. , Zeng, Xinlei, Truong, Dong‐Jiunn Jeffery , Schoof, Erwin M. , Searle, Brian C. , Searle, Brian C , Zeng, Xinlei, Ye, Zilu

Journal of Proteome Research | September 13, 2025 | Volume: 24 | Issue: 10 | Pages: 5116-5126

10.1021/acs.jproteome.5c00469 | PMID 40940309 Get It

AAPM TG report 330: EPID‐based quality assurance of linear accelerators
Sun, Baozhou, Yaddanapudi, Sridhar, Mutic, Sasa, Shi, Chengyu, McCurdy, Boyd M. C., Popple, Richard A., Lu, Minghui, Kim, Taeho, Clark, Jennifer R, Greer, Peter B, Yaddanapudi, Sridhar , Yaddanapudi, Sridhar , Sun, Baozhou, Mutic, Sasa, Shi, Chengyu, McCurdy, Boyd M. C., Popple, Richard A., Lu, Minghui, Kim, Taeho, Clark, Jennifer R, Greer, Peter B.

Medical Physics | September 13, 2025 | Volume: 52 | Issue: 9 | Pages: No page available

10.1002/mp.18114 Get It

Abstract Electronic portal imaging devices (EPIDs) have been in widespread clinical use for almost two decades due to favorable measurement characteristics such as fast image acquisition, high sensitivity and resolution, digital data format, long‐term stability, linear dose response, and large detection area. On‐board EPIDs are widely used as a quality assurance (QA) tool to monitor nearly every aspect of linear accelerator (linac) performance. In both the commercial QA equipment market and in clinical practice, there is a trend toward replacing conventional QA approaches with fully automated, EPID‐based QA tools. Despite widespread use, EPIDs are complex devices, and there has yet to be consensus or formal recommendations published by the AAPM for their use in routine linac QA. Task Group 330 (TG‐330) was, therefore, formed to provide guidelines and recommendations for physicists on the safe and appropriate use of EPIDs for linac QA. In particular, the report: (a) provides a comprehensive review of the characteristics and limitations of EPIDs as time‐resolved measurement devices and dosimeters; (b) summarizes the application of EPIDs for linac QA; (c) provides recommendations on efficient and effective implementations of EPID‐based QA techniques; (d) describes risks associated with the use of EPIDs for linac QA and provides examples of how risk analysis can be used to ensure the safe use of EPIDs for linac QA. Many of the guidelines in this report are drawn from the literature that is included in the references and from the collective experience of the task group members. This report does not provide recommendations on the implementation of EPID‐based patient‐specific IMRT or VMAT QA, which is the topic of AAPM's report from AAPM TG‐307.
Lung Disease in Children With Laryngotracheoesophageal Clefts
Hosfield, Emily A., Patten, Hannah C, Hopson, Puanani , Cofer, Shelagh A. , Wiedermann, Joshua P. , Boesch, R. Paul , Hopson, Puanani E, HC, Patten

Pediatric Pulmonology | September 12, 2025 | Volume: 60 | Issue: 9 | Pages: No page available

10.1002/ppul.71285 | PMID 40939098 Get It

ABSTRACT Introduction Laryngotracheoesophageal clefts (LTEC) are aspiration‐related lesions often assessed using swallow studies and symptoms like respiratory or feeding difficulties. However, these indicators are unreliable predictors of disease severity. Lung inflammation and injury, though significant concerns, are rarely and inconsistently evaluated or reported. As a result, the correlation between swallow study findings and actual pulmonary disease remains unclear. Methods A retrospective cohort of children with LTEC seen in our Aerodigestive Program between October 1, 2012, and September 30, 2023, who underwent videofluoroscopic swallow study (VFSS) or flexible endoscopic evaluation of swallowing (FEES) were included. Data collected included clinical history, risk factors, BAL, chest CT, impedance probe, VFSS/FEES findings, and FOIS‐P/I scores at baseline and follow‐up. Results Eight‐two subjects identified. Lung inflammation and bronchiectasis were common and correlated. Clinical factors, impedance probe, and the presence/severity of swallowing abnormalities on VFSS/FEES were not predictive of lung disease. Fifty‐seven patients underwent LTEC repair for a range of indications, only 49% based on CT and/or BAL findings. Of 57 children who had LTEC repair, only 49% were based on CT or BAL findings. LTEC repair was associated with modest improvement feeding and swallowing. Discussion Children with LTEC have a high prevalence of inflammatory lung disease and injury and undergo repair for a variety of reasons. Swallow studies detect functional swallowing issues but do not reliably identify lung disease. Despite this limitation, LTEC repair is linked to improved feeding and swallowing in some patients, though not all benefit.